Summit Therapeutics and GSK to Collaborate on Clinical Trial for Ivonescimab and Risvutatug Rezetecan in Solid Tumors.

Summit Therapeutics has entered a clinical trial collaboration with GSK to evaluate ivonescimab, a PD-1/VEGF bispecific antibody, in combination with GSK's B7-H3 antibody drug conjugate, risvutatug rezetecan, across multiple solid tumor settings, including small cell lung cancer. The study is expected to begin dosing patients in mid-2026. Each party will maintain rights to their respective products, and the agreement is mutually non-exclusive.